tbuckley/cabot-search huggingface dataset:
Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
Authors: Arianne Perez, Lynn Navale, John M. Rossi, Yueh-wei Shen, Yizhou Jiang, Marika Sherman, Armen Mardiros, Sean C. Yoder, William Y. Go, Steven A. Rosenberg, Jeff Wiezorek, Margo R. Roberts, David D. Chang, James N. Kochenderfer, Adrian Bot
Journal: Blood (2015)
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Authors: Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Ilaria Buondonno, Dario Ferrero, Mario Boccadoro, Chiara Dellacasa, Alessandro Busca, Domenico Novero, Benedetto Bruno
Journal: Journal of Hematology & Oncology (2016)

Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication. Standard treatment is high-dose (HD) corticosteroids. Steroid-refractory (SR) GvHD is associated with poor prognosis. At present, second-line treatment is ill-defined and includes a number of agents. Novel insights into the pathophysiology of acute GvHD (aGvHD) highlight the relevant role of the host inflammatory response governed by several kinase families, including Janus kinases (JAK)1/2. Ruxolitinib, a JAK1/2 inhibitor approved for intermediate-2/high-risk myelofibrosis, was recently employed in SR-GvHD with encouraging overall response rates. Clinical experience however remains limited. A 51-year-old male with refractory anemia with excess blast type-2 underwent a myeloablative allogeneic HSCT from a 9/10 HLA-matched unrelated donor after conditioning with busulfan and cyclophosphamide. GvHD prophylaxis consisted of cyclosporine, methotrexate, and thymoglobulin. CD34+ cells/kg infused were 8.69 × 106 kg. On day 29, the patient developed overall grade IV aGvHD with biopsy proven stage IV gastrointestinal (GI) GvHD refractory to HD corticosteroids. Patient conditions rapidly deteriorated and became critical despite the addition of mycophenolate mofetil and budesonide. On day 33, Ruxolitinib was started, and on day 39 the patient clinical conditions gradually improved. Complete resolution of aGvHD was also confirmed by histology on day 54. At 5 months from HSCT, the patient is well and in continuous hematological complete remission without flare of GvHD. Ruxolitinib was discontinued on day 156. Ruxolitinib is feasible and effective in SR-aGvHD though large prospective clinical trials are warranted.
Highly Efficient Multivalent 2D Nanosystems for Inhibition of Orthopoxvirus Particles
Authors: Benjamin Ziem, Hendrik Thien, Katharina Achazi, Constanze Yue, Daniel Stern, Kim Silberreis, Mohammad Fardin Gholami, Fabian Beckert, Dominic Gröger, Rolf Mülhaupt, Jürgen P. Rabe, Andreas Nitsche, Rainer Haag
Journal: Advanced Healthcare Materials (2016)

Efficient inhibition of cell–pathogen interaction to prevent subsequent infection is an urgent but yet unsolved problem. In this study, the synthesis and functionalization of novel multivalent 2D carbon nanosystems as well as their antiviral efficacy in vitro are shown. For this reason, a new multivalent 2D flexible carbon architecture is developed in this study, functionalized with sulfated dendritic polyglycerol, to enable virus interaction. A simple “graft from” approach enhances the solubility of thermally reduced graphene oxide and provides a suitable 2D surface for multivalent ligand presentation. Polysulfation is used to mimic the heparan sulfate‐containing surface of cells and to compete with this natural binding site of viruses. In correlation with the degree of sulfation and the grafted polymer density, the interaction efficiency of these systems can be varied. In here, orthopoxvirus strains are used as model viruses as they use heparan sulfate for cell entry as other viruses, e.g., herpes simplex virus, dengue virus, or cytomegalovirus. The characterization results of the newly designed graphene derivatives demonstrate excellent binding as well as efficient inhibition of orthopoxvirus infection. Overall, these new multivalent 2D polymer nanosystems are promising candidates to develop potent inhibitors for viruses, which possess a heparan sulfate‐dependent cell entry mechanism.
From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics
Authors: Shaheer Maher, Tushar Kumeria, Ye Wang, Gagandeep Kaur, Dina Fathalla, Gihan Fetih, Abel Santos, Fawzia Habib, Andreas Evdokiou, Dusan Losic
Journal: Advanced Healthcare Materials (2016)

Drug delivery using synthetic nanoparticles including porous silicon has been extensively used to overcome the limitations of chemotherapy. However, their synthesis has many challenges such as lack of scalability, high cost, and the use of toxic materials with concerning environmental impact. Nanoscale materials obtained from natural resources are an attractive option to address some of these disadvantages. In this paper, a new mesoporous biodegradable silicon nanoparticle (SiNP) drug carrier obtained from natural diatom silica mineral available from the mining industry is presented. Diatom silica structures are mechanically fragmented and converted into SiNPs by simple and scalable magnesiothermic reduction process. Results show that SiNPs have many desirable properties including high surface area, high drug loading capacity, strong luminescence, biodegradability, and no cytotoxicity. The in‐vitro release results from SiNPs loaded with anticancer drugs (doxorubicin) demonstrate a pH‐dependent and sustained drug release with enhanced cytotoxicity against cancer cells. The cells study using doxorubicin loaded SiNPs shows a significantly enhanced cytotoxicity against cancer cells compared with free drug, suggesting their considerable potential as theranostic nanocarriers for chemotherapy. Their low‐cost manufacturing using abundant natural materials and outstanding chemotherapeutic performance has made them as a promising alternative to synthetic nanoparticles for drug delivery applications.
Sensitivity, Specificity, and Predictive Values in the 'Sensitivity and Specificity of Clinical Diagnostics'
Authors: B. A. Woodruff, R. C. Baron
Journal: JAMA (1989)

<h3>To the Editor.—</h3> The measures of accuracy in clinical screening or diagnosis relate to the intrinsic ability of a procedure to identify correctly those persons with disease (sensitivity) and those persons without disease (specificity).<sup>1</sup>In a recent article entitled "The Sensitivity and Specificity of Clinical Diagnostics During Five Decades,"<sup>2</sup>the authors use the<i>terms clinical accuracy for a positive diagnosis and clinical accuracy for a negative diagnosis</i>and equate them by definition to the positive predictive value (the proportion of positive tests or diagnoses that correctly identify the presence of disease) and the negative predictive value (the proportion of negative tests that correctly identify the absence of disease), respectively. Unlikesensitivity and specificity, the predictive values are not properties inherent to the procedure itself, but vary with the prevalence of disease in the population tested. For example, the authors state that "the accuracy of the clinical diagnosis
Risk of Advanced Neoplasia Using the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool
Authors: Thomas F Imperiale, Menggang Yu, Patrick O Monahan, Timothy E Stump, Rebeka Tabbey, Elizabeth Glowinski, David F Ransohoff
Journal: JNCI Journal of the National Cancer Institute (2016)

There is no validated, discriminating, and easy-to-apply tool for estimating risk of colorectal neoplasia. We studied whether the National Cancer Institute's (NCI's) Colorectal Cancer (CRC) Risk Assessment Tool, which estimates future CRC risk, could estimate current risk for advanced colorectal neoplasia among average-risk persons.This cross-sectional study involved individuals age 50 to 80 years undergoing first-time screening colonoscopy. We measured medical and family history, lifestyle information, and physical measures and calculated each person's future CRC risk using the NCI tool's logistic regression equation. We related quintiles of future CRC risk to the current risk of advanced neoplasia (sessile serrated polyp or tubular adenoma ≥ 1 cm, a polyp with villous histology or high-grade dysplasia, or CRC). All statistical tests were two-sided.For 4457 (98.5%) with complete data (mean age = 57.2 years, SD = 6.6 years, 51.7% women), advanced neoplasia prevalence was 8.26%. Based on quintiles of five-year estimated absolute CRC risk, current risks of advanced neoplasia were 2.1% (95% confidence interval [CI] = 1.3% to 3.3%), 4.8% (95% CI = 3.5% to 6.4%), 6.4% (95% CI = 4.9% to 8.2%), 10.0% (95% CI = 8.1% to 12.1%), and 17.6% (95% CI = 15.5% to 20.6%; P < .001). For quintiles of estimated 10-year CRC risk, corresponding current risks for advanced neoplasia were 2.2% (95% CI = 1.4% to 3.5%), 4.8% (95% CI = 3.5% to 6.4%), 6.5% (95% CI = 5.0% to 8.3%), 9.3% (95% CI = 7.5% to 11.4%), and 18.4% (95% CI = 15.9% to 21.1%; P < .001). Among persons with an estimated five-year CRC risk above the median, current risk for advanced neoplasia was 12.8%, compared with 3.7% among those below the median (relative risk = 3.4, 95 CI = 2.7 to 4.4).The NCI's Risk Assessment Tool, which estimates future CRC risk, may be used to estimate current risk for advanced neoplasia, making it potentially useful for tailoring and improving CRC screening efficiency among average-risk persons.
Randomized placebo-controlled trial of hen's egg consumption for primary prevention in infants
Authors: Johanna Bellach, Veronika Schwarz, Birgit Ahrens, Valérie Trendelenburg, Özlem Aksünger, Birgit Kalb, Bodo Niggemann, Thomas Keil, Kirsten Beyer
Journal: Journal of Allergy and Clinical Immunology (2016)
Continued spread of Zika raises many research questions, WHO says
Authors: Anne Gulland
Journal: BMJ (2016)

The continued spread of the Zika virus to new countries means that it remains an international public health emergency, the Zika emergency committee of the World Health Organization has said.

Both Singapore and Guinea-Bissau reported their first cases in the past two months. Singapore first notified WHO of the presence of the virus at the end of August,1 and 115 cases were confirmed by 2 September. Guinea-Bissau has reported four cases of Zika and five cases of microcephaly, the congenital neurological condition that has been linked with the virus in Brazil. An epidemiological link between the Zika …
Perfusion à haute dose d’oméprazole versus second endoscopique systématique dans la prévention de la récidive d’hémorragie ulcéreuse: un essai randomisé contrôlé
Journal: Endoscopy (2016)

Le risque de récidive hémorragique est un élément déterminant du pronostic des hémorragies digestives ulcéreuses. Dans cette étude du centre de référence de Hong Kong, les auteurs ont comparé prospectivement dans un essai randomisé et contrôlé la perfusion de 80 mg en bolus d’oméprazole suivi d’une perfusion de 8 mg/h pendant 72 heures à la réalisation systématique d’une seconde endoscopie entre 16 et 24 hs chez des patients traités par 40 mg d’oméprazole par voie veineuse en bolus toutes les 12 hs pendant 72 heures.
Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
Authors: Alberto Bouzas-Mosquera
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma
Authors: Sarah Belliotti, Juan Gu, Cory Mavis, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2013)
Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse
Authors: Joon Ho Moon, Sang Kyun Sohn, Naheed Alam, Jieun Uhm, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, John Kuruvilla, Dennis Dong Hwan Kim
Journal: Blood (2013)
Characteristics and outcomes of invasive lobular of carcinoma and invasive ductal carcinoma of the breast: SEER/Medicare 1992-2002.
Authors: A. Thomas, Y. Xie, K. B. Wright, J. Brooks
Journal: Journal of Clinical Oncology (2010)

e16520 Background: Invasive lobular carcinoma (ILC) is increasingly recognized as having a biology distinct from the more common invasive ductal carcinoma (IDC). Series comparing ILC and IDC are often smaller and single-institution. Methods: Patients (pts) 66 yrs and older with first diagnosis of stage I and II breast cancer from 1992-2002 were identified in SEER-Medicare linked data. Patient characteristics were compared across histology status. Histology status was interacted with four treatments: breast-conserving surgery (BCS) with and without radiation therapy (XRT) and mastectomy (M) with and without XRT. Multivariate logistic regressions were performed to estimate the effects of histology specific treatments on 5-yr overall mortality (OM) with a set of demographic, clinical, and socioeconomic variables controlled. Results: Data from 29,782 pts were evaluated, 26,099 with IDC and 3,683 with ILC. Five-yr OM was 24.8%. Estrogen receptor was positive in 68.6% of IDC pts and 74.8% of ILC pts. 61.3% of IDC pts and 51.9% of ILC pts were Stage 1 at diagnosis. Tumor size was <10 mm in 30.6% and 21.1 % of IDC and ILC pts respectively. Tumor size of >30 mm was seen in 9.3% and 15.9% of IDC and ILC pts respectively. Lymph nodes were positive in 21.1% of IDC pts and 21.9% of ILC pts. ILC represented 11.5% and 13.3 % of diagnoses in 1992 and 1999 respectively. Five-yr OM by histology and treatment is reported in the Table. For the entire group, the odds ratio (OR) of 5-yr OM was higher for pts who received chemotherapy during the year after diagnosis (OR = 1.36, p<0.001). Conclusions: This large series of pts >65 yrs with stage I and II breast cancer confirms previous understandings of ILC at presentation. A 5-yr survival advantage was seen for ILC pts. For pts with IDC, mortality at 5 yrs was significantly lower with BCS and XRT than for all other forms of local therapy. These differences were not seen with ILC. 5-yr overall mortality Variable Reference group OR p value ILC (n=3,683) IDC (n=26,099) 0.89 0.01 ILC-BCS+XRT IDC-BCS+XRT 1.01 0.89 IDC - M IDC-BCS+XRT 1.31 <0.001 ILC - M IDC-BCS+XRT 1.12 0.11 IDC – M+XRT IDC-BCS+XRT 1.56 <0.001 ILC – M+XRT IDC-BCS+XRT 1.09 0.51 IDC - BCS IDC-BCS+XRT 2.07 <0.001 ILC - BCS IDC-BCS+XRT 2.34 <0.001 No significant financial relationships to disclose.
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
Authors: D Bauwens, M Maerevoet, Lucienne Michaux, I Theate, Anne Hagemeijer-Hausman, M Stul, N Straetmans, P Leveugle, S Costantini, A Ferrant, E Van den Neste
Journal: Annals of Oncology (2005)
Tumor-associated macrophages correlate with microvascular density and endothelial area in locally advanced colorectal cancer patients undergone to surgery
Authors: I. Marech, M. Ammendola, R. Sacco, G. Sammarco, V. Zuccalà, N. Zizzo, C. Leporini, M. Luposella, R. Patruno, G. Filippelli, E. Russo, M. Porcelli, C.D. Gadaleta, G. De Sarro, G. Ranieri
Journal: Annals of Oncology (2015)
Building a Lean, Mean Patient Care Machine
Authors: Juliet June Ray, Seth A. Spector
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer
Authors: Barbara Grünwald, Jennifer Vandooren, Erica Locatelli, Pierre Fiten, Ghislain Opdenakker, Paul Proost, Achim Krüger, Jean Paul Lellouche, Liron Limor Israel, Louis Shenkman, Mauro Comes Franchini
Journal: Journal of Controlled Release (2016)
D4-03: SCF protein (Skp2, CUL1) regulate the E2F1 dependent transcriptional activity and cyclin E in human lung tumors
Authors: Elisabeth Brambilla, Caroline Salon, Galia Merdzhanova, Sylvie Lantuejoul, Sylvie Gazzeri, Béatrice Eymin
Journal: Journal of Thoracic Oncology (2007)
Epinephrine pen maker offers discounts after alleged price hiking
Authors: Michael McCarthy
Journal: BMJ (2016)

Mylan NV, which makes the epinephrine auto-injection device EpiPen, has announced that it will expand its discount and coupon programs for uninsured and under-insured patients and has promised to sell an identical generic device at half the price of the branded product, after criticism of its pricing policy.

However, critics remain unsatisfied and have called for government action to force Mylan to lower its prices further.

“The company must roll back its unjustified and outrageous price increases,” said Robert Weissman, president of the consumer group Public Citizen. On 30 August, Public Citizen and several other organizations delivered petitions with a reported 700 000 signatures, protesting against the drug’s price, to …
The role of systemic therapy after local treatment in breast cancer patients with first presentation of brain metastases recurrence.
Authors: Anna Niwinska, Tadeusz Pienkowski, Katarzyna Pogoda, Agnieszka Irena Jagiello-Gruszfeld, Izabela Lemanska, Renata Sienkiewicz-Kozlowska, Ewa Glinka - Malasnicka, Ewa Szombara, Elzbieta Brewczynska, Anna Gorniak, Roman Dubianski, Zbigniew Nowecki
Journal: Journal of Clinical Oncology (2016)

e13527 Background: The role of systemic treatment was assessed after local therapy for breast cancer patients who developed central nervous system (CNS) metastasesas a first and isolated recurrence. Methods: Subjects were 128 breast cancer patients with brain metastases as the first and isolated site of recurrence that were selected from 673 consecutive breast cancer patients with brain metastases treated at the same institution. Results: Median survival from brain metastases in patients with and without systemic treatment after local therapy was respectively 15 and 4 months (p < 0.001). In patients with a Karnofsky Performance Status > = 70 and those < 70, survival was respectively 16 and 5.5 months (p< 0.001). The median survival from brain metastasis in patients with solitary brain metastasis, with and without systemic treatment after local therapy, was respectively 22 and 7 months (p= 0.003). In the triple-negative subtype group, median survival following the diagnosis of brain metastases in those treated and untreated with systemic therapy was respectively 10 and 5 months, (p= 0.212). Median survival after brain metastases diagnosis for the two HER2-positive subtypes (HER2+, ER/PgR+ and HER2+ ER-PgR-), post and without systemic therapy, was respectively 16 and 4 months, (p< 0.001) and in the luminal subtype 20 and 3 months were respectively observed (p= 0.102). Cox multivariate analysis demonstrated that good performance status, solitary brain metastasis and systemic therapy undertaken after local treatment were factors which prolonged survival. However patient survival was adversely affected by those having leptomeningeal metastasis associated with brain parenchymal lesions. Conclusions: Systemic therapy, undertaken after local treatment improved survival in those patients with breast cancer and brain metastases as the site of first recurrence. Further study is required in order to fully establish the role of systemic treatment for this patient group.
SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression
Authors: Juliana Carvalho Santos, Estefania Carrasco-Garcia, Mikel Garcia-Puga, Paula Aldaz, Milagrosa Montes, Maria Fernandez-Reyes, Caroline Candida de Oliveira, Charles H Lawrie, Marcos J. Araúzo-Bravo, Marcelo Lima Ribeiro, Ander Matheu
Journal: Cancer Research (2016)

Abstract Gastric cancer remains one of the leading causes of global cancer mortality due to therapy resistance, with Helicobacter pylori (H. pylori) infection being a major risk factor. In this study, we report the significance of an elevation of the stem cell regulator SOX9 in bacteria-infected human gastritis and cancer samples, paralleling increased levels of TNFα. SOX9 elevation was more intense in specimens containing the pathogenically significant cagA+ strains of H. pylori. Notably, we found that SOX9 was required for bacteria-induced gastric cancer cell proliferation, increased levels of β-catenin, and acquisition of stem cell–like properties. Analysis of three large clinical cohorts revealed elevated SOX9 levels in gastric cancer with advanced tumor stage and poor patient survival. Functionally, SOX9 silencing in gastric cancer cells enhanced apoptosis and senescence, concomitantly with a blockade to self-renewal and tumor-initiating capability. Paralleling these effects, we also found SOX9 to mediate cisplatin chemoresistance associated with reduced disease-free survival. Mechanistic interactions between SOX9 and β-catenin expression suggested the existence of a regulatory role for SOX9 targeting the WNT canonical pathway. Taken together, our findings establish the significance of SOX9 in gastric cancer pathobiology and heterogeneity, with implications for targeting WNT–SOX9 signaling as a rational therapeutic strategy. Cancer Res; 76(22); 6735–46. ©2016 AACR.